SGMT Stock Analysis: Buy, Sell, or Hold?
SGMT - Sagimet Biosciences Inc. Series A Common Stock
$10.23
-0.03 (-0.24%)
▼
5d:
-1.97%
30d:
+44.63%
90d:
+44.22%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When SGMT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SGMT shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SGMT shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: SGMT is currently trading at $10.22, which is considered extended relative to its 30-day fair value range of $7.19 to $9.89.
Technical Outlook: Technically, SGMT is in a uptrend. Immediate support is located at $9.07, while resistance sits at $11.15.
Market Sentiment: SGMT scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $28.60 (+174.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SGMT is in a uptrend. Immediate support is located at $9.07, while resistance sits at $11.15.
Market Sentiment: SGMT scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $28.60 (+174.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$7.19 -
$9.89
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 174.2% below Wall St target ($28.60)
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.19 -
$9.89
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$9.07
Resistance Level
$11.15
Current Trend
Uptrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.78
Wall Street Target
$28.60
(+174.2%)
Share & Embed Analysis
Last updated: August 24, 2026 3:02 PM ET
Data refreshes hourly during market hours. Next update: 4:02 PM
Data refreshes hourly during market hours. Next update: 4:02 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SGMT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 46 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 45 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 68 BUY |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
13 analysts |
$19 | 51 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 32 SELL |
